Reuters logo
BRIEF-MediciNova completes enrollment in the phase 2 trial of MN-166 in methamphetamine dependence
September 19, 2017 / 10:36 AM / in a month

BRIEF-MediciNova completes enrollment in the phase 2 trial of MN-166 in methamphetamine dependence

Sept 19 (Reuters) - MediciNova Inc

* MediciNova announces the completion of enrollment in the phase 2 clinical trial of MN-166 (ibudilast) in methamphetamine dependence

* MediciNova Inc - final results of phase 2 MN-166 study expected by Q1 of 2018 Source text for Eikon: Further company coverage:

0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below